BiotechTube

SOM230 s.c.

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Cushing's Syndrome

Conditions

Cushing's Syndrome

Trial Timeline

Apr 1, 2004 → —

NCT ID
NCT00088608

About SOM230 s.c.

SOM230 s.c. is a phase 2 stage product being developed by Novartis for Cushing's Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT00088608. Target conditions include Cushing's Syndrome.

What happened to similar drugs?

2 of 10 similar drugs in Cushing's Syndrome were approved

Approved (2) Terminated (1) Active (7)
✅Pasireotide s.c. + Sitagliptin + Liraglutide + Insulin + Pasireotide LAR + MetforminNovartisApproved
✅Pasireotide + Cabergoline + Pasireotide LARRecordatiApproved
🔄pasireotide LAR + SOM230 LAR 30 mg + SOM230 LAR 10 mgNovartisPhase 3
🔄Pasireotide sub-cutaneousNovartisPhase 3
🔄osilodrostat + osilodrostat PlaceboNovartisPhase 3
🔄PasireotideNovartisPhase 3
🔄mifepristoneCorcept TherapeuticsPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00088608Phase 2Completed

Competing Products

18 competing products in Cushing's Syndrome

See all competitors
ProductCompanyStageHype Score
AZD4017 and prednisolone + Placebo Oral Tablet and prednisoloneAstraZenecaPhase 2
35
pasireotide LAR + SOM230 LAR 30 mg + SOM230 LAR 10 mgNovartisPhase 3
40
Pasireotide sub-cutaneousNovartisPhase 3
40
osilodrostat + osilodrostat PlaceboNovartisPhase 3
40
OsilodrostatNovartisPhase 2
35
PasireotideNovartisPhase 3
40
Pasireotide s.c. + Sitagliptin + Liraglutide + Insulin + Pasireotide LAR + MetforminNovartisApproved
43
Lu AG13909LundbeckPhase 2
39
OsilodrostatRecordatiPre-clinical
23
Pasireotide + Cabergoline + Pasireotide LARRecordatiApproved
40
osilodrostatRecordatiPhase 2
32
OsilodrostatRecordatiPre-clinical
27
mifepristoneCorcept TherapeuticsPhase 3
37
CORT125134Corcept TherapeuticsPhase 2
32
Cushing's syndrome confirmationCorcept TherapeuticsPre-clinical
15
MifepristoneCorcept TherapeuticsPhase 3
37
mifepristoneCorcept TherapeuticsPhase 3
37
mifepristoneCorcept TherapeuticsPhase 3
29